Health

Health economics outcomes research

We are passionate about helping clients rigorously evaluate and clearly communicate the value of their products.

We apply scientific rigor across both traditional and innovative approaches, from HTA-compliant cost-effectiveness and budget impact models to broader assessments of the value that therapies and other interventions bring to health systems and society.

Combining deep knowledge with innovation

Our HEOR (Health Economics and Outcomes Research) team navigates the complexities of generating robust evidence to meet the diverse needs of payers, HTA (Health Technology Assessment) agencies, healthcare providers, and local prescribers. Our team includes experienced health economists, evidence synthesis specialists, actuaries, and statisticians who focus on gathering and synthesizing clinical and economic evidence to clearly demonstrate the value a product delivers for patients, healthcare systems, and society at large.

We combine methodological rigor with a commitment to innovation. Our goal is to generate evidence that demonstrates not only clinical and economic outcomes, but also the broader value therapies bring to patients, payers, and healthcare decision-makers.

Collaboration at the core of our approach

By working closely with our real-world evidence and market access teams, we ensure our recommendations are holistic, integrating multiple perspectives to deliver more relevant and effective outcomes. This synergy strengthens our ability to provide impactful solutions that resonate with clients and their stakeholders alike.

We support our clients across the following areas:

Evidence synthesis

Systematic literature reviews
Network meta-analysis

Economic modeling and data analysis

Cost-effectiveness models
Budget impact models
Disease transmission models
Natural history models
Statistical analyses

Innovative value-based reimbursement solutions

Internal revenue modeling
Design, implementation, and administration of innovative reimbursement agreements

Our experts

View all experts

Featured insights

Reimagining patient support in the era of MFN: A strategic imperative for manufacturers

Lee Ann Steadman explores how the Most Favored Nations (MFN) policy is reshaping drug pricing and why manufacturers must reimagine patient support programs as strategic, sustainable models to protect access and deliver long-term value.

Read now

Achieving equitable representation in clinical trials

Matthew Hankins examines how integrating real-world evidence into diversity action plans can help clinical trial sponsors comply with FDA diversity guidance.

Read now

Investment Uncut: Kevin Patterson - Are pharma’s short-term pains a long-term opportunity?

In this podcast, our hosts are joined by Kevin Patterson to explore whether current challenges in the pharmaceutical sector could actually present a long-term investment opportunity.

Listen now

The fiscal value of treatment and prevention

Discover insights shared at a roundtable discussion on the fiscal value of treatment and prevention which highlighted the need for a more integrated approach to healthcare investment.

Discover more